Clinical science review: Current aspects of thrombolytic therapy in women with acute myocardial infarction

Angiology

Volumn 47, Issue 1, 1996, Pages 23-33

  Hussain, K M A ^a   Gould, L ^a   Sosler, B ^a   Bharathan, T ^a   Reddy, C V R ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; GRAFT PATENCY; HEART ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; RECANALIZATION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030031785     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979604700104     Document Type: Article

References (83)

1. American Heart Association: Silent epidemic: The truth about women and heart disease. Dallas: American Heart Association, 1988, p 2.
2. Norris R, Brandt P, Caughey D, et al: A new coronary prognostic index. Lancet 1:274-278, 1969.
3. Johansson S, Bergstrand R, Ulvenstam G, et al: Sex differences in preinfarction characteristics and longterm survival among patients with myocardial infarction. Am J Epidemiol 119:610-623, 1984.
4. Tofler G, Stone P, Muller J, et al: Effects of gender and race on prognosis after myocardial infarction: Adverse prognosis for women, particularly black women. J Am Coll Cardiol 9:473-482, 1987.
5. Kannel W, Sorlie P, McNamara P: Prognosis after myocardial infarction. The Framingham Study. Am J Cardiol 44:53-59, 1979.
6. Puletti M, Sunseri L, Curione M, et al: Acute myocardial infarction: Sex-related differences in prognosis. Am Heart J 108:63-66, 1984.
7. Marmor A, Geltman E, Schechtman K, et al: Recurrent myocardial infarction: Clinical predictors and prognostic implications. Circulation 66:415-421, 1982.
8. Peter T, Harper R, Luxton M, et al: The influence of age on complications and mortality. Med J Aust 1:189-191, 1978.
9. Wenger N: Coronary disease in women. Annu Rev Med 36:285-294, 1985.
10. Johansson S, Vedin A, Wilhelmsson C: Myocardial infarction in women. Epidemiol Rev 5:67-94, 1983.
11. Handler J, Warren S, Vieweg W: Risk factor and sex differences in single versus multiple vessel coronary artery disease. South Med J 74:1451-1453, 1981.
12. Reed D, Yano K: Predictors of arteriographically defined stenosis in the Honolulu Heart Program. Am J Epidemiol 134:111-122, 1991.
13. McGill H Jr: The cardiovascular pathology of smoking. Am Heart J 115:250-257, 1988.
14. Gomez M, Karagounis L, Allen A, et al: Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol 72:373-378, 1993.
15. Chun B, Dobson A, Heller R: Smoking and the incidence of coronary heart disease in an Australian population. Med J Aust 159:508-512, 1993.
16. Wang X, Tam C, McCredie R, et al: Determinants of severity of coronary artery disease in Australian men and women. Circulation 89:1974-1981, 1994.
17. Murdough C: Coronary artery disease in women. J Cardiovasc Nurs 4:35-50, 1990.
18. Naeim F, De la Maza L, Robbins S: Cardiac rupture during MI. Circulation 45:1231-1239, 1972.
19. Oblath R, Levinson D, Griffith G: Factors influencing rupture of the heart after acute myocardial infarction. JAMA 149:1276-1281, 1952.
20. Loukinen K, O'Neill W, Laufer N, et al: Myocardial rupture complicating t-PA therapy of acute myocardial infarction. J Am Coll Cardiol 13(suppl A):94A, 1989.
21. Gorlin R: Balancing the benefits, risks and unknowns of thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 11:1349-1354, 1988.
22. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397-401, 1986.
23. GISSI Study Group: Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI Study. Lancet 1:871-874, 1987.
24. Wilcox R, Olsson C, Skene A, et al: Trial of t-PA for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet ii:525-530, 1988.
25. ISIS-2 (Second International Study of Infarct Survival) Collaboration Group: Randomized trial of intravenous, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet ii:349-360, 1988.
26. European Working Party Trial (EWPT): Streptokinase in recent myocardial infarction: A controlled multicenter trial. Br Med J 3:325-331, 1971.
27. Rao A, Pratt C, Berke A, et al: Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibriolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988.
28. Califf R, Topol E, George B, et al: Hemorrhagic complications associated with the use of intravenous tissue plasminogen activators in the treatment of acute myocardial infarction. Am J Med 85:353-359, 1988.
29. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of Streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339:753-770, 1992.
30. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993.
31. Sloan M, Gore J: Ischemice stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol 69.12A-38A, 1992.
32. Califf R, Stump D, Topol E, et al: Overview of bleeding risk from the TAMI Trials: Two agents are better than one. J Am Coll Cardiol 13:198A, 1989.
33. Simoons M, Arnold A, Betriu A, et al: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1:197-202, 1988.
34. Topol E, Califf R, George B, et al: Insights derived from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trials. J Am Coll Cardiol 12:24A-31A, 1988.
35. Braunwald E, Knatterud G, Passammani E, et al: Announcement of a critical change in thrombolysis in myocardial infarction trial (letter). J Am Coll Cardiol 9:467, 1987.
36. Anderson H, Willerson J: Thrombolysis in acute myocardial infarction. N Engl J Med 329:703-709, 1993.
37. Herrick J: Certain clinical features of sudden obstruction of the coronary arteries. Trans Assoc Am Physicians 27:100-116, 1912.
38. Chazov E, Mateeva L, Maseav A, et al: Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 48:8-19, 1978.
39. deWood M, Spores J, Notske R, et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902, 1980.
40. Kennedy J, Ritchie J, David K, et al: Western Washington Randomized Trial of Intracoronary Streptokinase in acute myocardial infarction. N Engl J Med 309:1477-1982, 1983.
41. White H, Norris R, Brown M, et al: Effect of intravenous Streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 317:850-855, 1987.
42. ISAM Study Group: A prospective trial of intravenous Streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 314:1465-1471, 1986.
43. TIMI Study Group: The Thrombolysis in Acute Myocardial Infarction (TIMI) trial. Phase 1 findings. N Engl J Med, 312:932-936, 1985.
44. Mathey D, Schofer J, Sheehan F, et al: Improved survival up to four years after early coronary thrombolysis. Am J Cardiol 61:524-529, 1988.
45. Galvani M, Ottani F, Ferrini D, et al: Patency of the infarct related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. Am J Cardiol 71:1-7, 1993.
46. Merx W, Dorr R, Rentrop P, et al: Evaluation of effectiveness of intracoronary Streptokinase infusion in acute myocardial infarction: Post-procedure management and hospital course in 204 patients. Am Heart J 102:1181-1187, 1981.
47. Been M, Debono D, Muir A: Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J 53:253-259, 1985.
48. George B, Candela R, Frazier R, et al: The paradox of high success of thrombolytic therapy and poor clinical elderly women with acute myocardial infarction. Circulation 78(suppl II):II-211, 1988.
49. Califf R, Topol E, George B, et al: Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. Circulation 77:1090-1099, 1988.
50. Morgan C, Roberts R, Haq A, et al: Coronary patency, infarct size and left ventricular function after thrombolysis therapy for acute myocardial infarction: Results from the Tissue Plasminogen Activator: Toronto (TPAT) placebo-controlled trial. J Am Coll Cardiol 17:1451-1457, 1991.
51. Braunwald E: Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expected? Circulation 79:441-444, 1989.
52. Fortin D, Califf R: Long-term survival from acute myocardial infarction: Salutary effects of an open vessel. Am J Med 88:1-9N-1-15N, 1990.
53. Siu S, Nidorf S, Galambos G, et al: The effect of the late patency of the infarct-related coronary artery on left ventricular morphology and regional function after thrombolysis. Am Heart J 124:265-272, 1992.
54. Kasper W, Erbel R, Meinertz T, et al: Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction. J Am Coll Cardiol 4:357-363, 1984.
55. Multicenter Post-infarction Research Group: Risk stratification and survival after myocardial infarction. N Engl J Med 309:331-336, 1983.
56. Shah P, Pichler M, Berman D, et al: Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction. Am J Cardiol 45:542-546, 1980.
57. Marchlinski F, Buxton F, Waxman F, et al: Identifying patients at risk of sudden death after myocardial infarction: Value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 52:1190-1196, 1983.
58. O'Neill W, Topol E, Pitt B: Reperfusion therapy of acute myocardial infarction. Prog Cardiovasc Dis 30:235-266, 1988.
59. Sheehan F: Determinants of improved left ventricular function after thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 9:937-944, 1987.
60. Koren G, Weiss A, Hasin T, et al: Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 313:1384-1389, 1985.
61. Zaret B, Battler A, Berger H, et al: Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Nuclear Cardiology. Circulation 70:768A-781A, 1984.
62. Given B, Lee T, Stone P, et al: Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. Arch Intern Med 145:281-285, 1985.
63. Topol E, Traill T, Fortuin N: Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 312:277-283, 1985.
64. Shapiro L: A prospective study of heart disease in diabetes mellitus. Am J Med 209:55-68, 1984.
65. Starling M, Dell'Italia L, Chandhuri T, et al: First transit and equilibrium radionuclide angiography in patients with inferior transmural myocardial infarction: Criteria for the diagnosis of associated hemodynamically significant RV infarction. J Am Coll Cardiol 4:923-930, 1984.
66. Sharpe N, Botvinick E, Sharmes D, et al: The noninvasive diagnosis of RV infarction. Circulation 57:483-490, 1978.
67. Shah P, Maddahi J, Berman D, et al: Scintographically detected predominant RV dysfunction in acute myocardial infarction: Clinical and hemodynamic correlates and implications for therapy and prognosis. J Am Coll Cardiol 6:1264-1272, 1985.
68. Dell'Italia L, Starling M, O'Rouke R: Physical examination for exclusion of hemodynamically important RV infarction. Ann Intern Med 99:608-611, 1983.
69. Schuler G, Huffman M, Schwarz F, et al: Effect of successful thrombolytic therapy on right ventricular function in acute inferior wall myocardial infarction. Am J Cardiol 54:951-957, 1984.
70. Verani M, Tortoledo F, Batty J, et al: Effect of coronary artery recanalization on RV function in patients with acute myocardial infarction. J Am Coll Cardiol 5:1029-1035, 1985.
71. Berger P, Ruocco N, Ryan T, et al: Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction (TIMI)-II trial. Am J Cardiol 71:1148-1152, 1993.
72. Vatterott P, Hammill S, Bailey K, et al: Reperfusion reduces late potentials independently of left ventricular function (abstract). Circulation 80(suppl 2):II-314, 1989.
73. Gang E, Lew A, Hong M, et al: Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 321:712-716, 1989.
74. Becker R: Coronary thrombolysis in women. Cardiology 77(suppl 2):110-123, 1990.
75. Tobin J, Wassertheil-Smoller S, Wexler J: Sex bias in considering coronary bypass surgery. Ann Intern Med 107:19-25, 1987.
76. Khan S, Nessim S, Gray R, et al: Increased mortality of women in coronary artery bypass surgery: Evidence for referral bias. Ann Intern Med 112:561-567, 1990.
77. Ayanian J, Epstein A: Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 325:221-225, 1991.
78. Steingart R, Packer M, Hamm P, et al: Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 325:226-230, 1991.
79. Gillum R, Feinleib M: Cardiovascular disease in the United States: Mortality, prevalence and incidence. In: Prognosis and Risk Assessment in Cardiovascular Disease, ed. by Kapoor A, Singh B. New York: Churchill Livingstone, 1993, pp 49-59.
80. Goldberg R, Gorak E, Yarzebski J, et al: A community-wide perspective of gender difference and temporal trends in the incidence and survival rates following acute myocardial infarction and out-of-hospital deaths due to coronary heart disease. Circulation 87:1947-1953, 1993.
81. Sempos C, Cooper R, Kover M, et al: Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health 78:1422-1427, 1988.
82. Gillum R: Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 23:1273-1277, 1993.
83. Becker R, Terrin M, Ross R, et al: Comparison of clinical outcomes for women and men after acute myocardial infarction. Ann Intern Med 120:638-645, 1994.